JP2016534062A5 - - Google Patents

Download PDF

Info

Publication number
JP2016534062A5
JP2016534062A5 JP2016525504A JP2016525504A JP2016534062A5 JP 2016534062 A5 JP2016534062 A5 JP 2016534062A5 JP 2016525504 A JP2016525504 A JP 2016525504A JP 2016525504 A JP2016525504 A JP 2016525504A JP 2016534062 A5 JP2016534062 A5 JP 2016534062A5
Authority
JP
Japan
Prior art keywords
immune complex
lyophilized composition
spdb
complex preparation
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016525504A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016534062A (ja
JP6813355B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2014/072558 external-priority patent/WO2015059147A1/en
Publication of JP2016534062A publication Critical patent/JP2016534062A/ja
Publication of JP2016534062A5 publication Critical patent/JP2016534062A5/ja
Application granted granted Critical
Publication of JP6813355B2 publication Critical patent/JP6813355B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016525504A 2013-10-25 2014-10-21 新規な安定製剤 Expired - Fee Related JP6813355B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13190276 2013-10-25
EP13190276.9 2013-10-25
PCT/EP2014/072558 WO2015059147A1 (en) 2013-10-25 2014-10-21 A novel stable formulation

Publications (3)

Publication Number Publication Date
JP2016534062A JP2016534062A (ja) 2016-11-04
JP2016534062A5 true JP2016534062A5 (OSRAM) 2018-12-27
JP6813355B2 JP6813355B2 (ja) 2021-01-13

Family

ID=49552164

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016525504A Expired - Fee Related JP6813355B2 (ja) 2013-10-25 2014-10-21 新規な安定製剤

Country Status (15)

Country Link
US (2) US20160250349A1 (OSRAM)
EP (1) EP3060256B1 (OSRAM)
JP (1) JP6813355B2 (OSRAM)
CY (1) CY1121791T1 (OSRAM)
DK (1) DK3060256T3 (OSRAM)
ES (1) ES2735645T3 (OSRAM)
HR (1) HRP20191053T1 (OSRAM)
HU (1) HUE045020T2 (OSRAM)
LT (1) LT3060256T (OSRAM)
PL (1) PL3060256T3 (OSRAM)
PT (1) PT3060256T (OSRAM)
RS (1) RS58856B1 (OSRAM)
SI (1) SI3060256T1 (OSRAM)
TR (1) TR201909034T4 (OSRAM)
WO (1) WO2015059147A1 (OSRAM)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR076284A1 (es) 2009-04-29 2011-06-01 Bayer Schering Pharma Ag Inmunoconjugados de antimesotelina y usos de los mismos
PT3570882T (pt) * 2017-01-19 2022-01-11 Bayer Pharma AG Nova formulação estável para anticorpos fxia
EP3673918A4 (en) 2017-08-23 2021-05-19 Daiichi Sankyo Company, Limited PREPARATION OF AN ANTIBODY INGREDIENT CONJUGATE AND LYOPHILIZATION FOR IT
WO2020234114A1 (en) 2019-05-21 2020-11-26 Bayer Aktiengesellschaft A novel stable high concentration formulation for anetumab ravtansine
WO2023230098A1 (en) 2022-05-23 2023-11-30 Logicbio Therapeutics, Inc. Gene therapy compositions and methods of use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX342007B (es) * 2003-05-14 2016-09-09 Immunogen Inc Composicion de farmaco conjugado.
EA014513B1 (ru) * 2005-08-03 2010-12-30 Иммьюноджен, Инк. Композиция иммуноконъюгата
TW200806315A (en) * 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
EP1854478A1 (en) * 2006-05-12 2007-11-14 Cytos Biotechnology AG Nicotine-carrier vaccine formulation
AR076284A1 (es) * 2009-04-29 2011-06-01 Bayer Schering Pharma Ag Inmunoconjugados de antimesotelina y usos de los mismos
KR102023496B1 (ko) * 2011-04-21 2019-09-20 시애틀 지네틱스, 인크. 신규 결합제-약물 콘주게이트 (adc) 및 그의 용도
CA2831572C (en) * 2011-05-02 2019-11-26 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
AR086823A1 (es) * 2011-06-30 2014-01-22 Genentech Inc Formulaciones de anticuerpo anti-c-met, metodos

Similar Documents

Publication Publication Date Title
HRP20200434T1 (hr) Stabilne vodene formulacije adalimumaba
PE20170780A1 (es) Formulacion estable de proteina en solucion que contiene una alta concentracion de un anticuerpo anti-vegf
JP2016034978A5 (OSRAM)
EA201591524A1 (ru) Производные 2-аминопиримидина для лечения вирусных инфекций
EA201600305A1 (ru) Вариант белка opc2 pcv2 и содержащие его вирусоподобные частицы
EA201492021A1 (ru) Антительный состав
JP2016534062A5 (OSRAM)
JP2016513069A5 (OSRAM)
MX2017007178A (es) Formulaciones liquidas estables de virus de vacuna.
JP2017531682A5 (OSRAM)
MX383706B (es) Composiciones de cenicriviroc y métodos para elaborarlas y usarlas.
EA201590667A1 (ru) Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний
CN108026053A8 (zh) 作为mIDH1抑制剂的稠合的咪唑类化合物
EA201490610A1 (ru) Соединения и способы усиления врожденных иммунных ответов
JP2016510326A5 (OSRAM)
MX2021006021A (es) Procedimiento de disminucion de la inmunogenicidad de proteinas y peptidos.
JP2016539921A5 (OSRAM)
AR103544A1 (es) FORMULACIONES FARMACÉUTICAS PARA ANTICUERPOS ANTI-TNF-a
CO2016003340A2 (es) Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
HK1251481A1 (zh) 使用白介素-17(il-17)拮抗剂治疗放射学阴性中轴型脊柱关节炎的方法
PH12018000197A1 (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
JP2015520196A5 (OSRAM)
EA201790223A1 (ru) Водный препарат, содержащий парацетамол и ибупрофен
UA110979C2 (uk) Рідка фармацевтична композиція, яка включає нітизинон
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний